Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

The Prostate

Showing results (1331-1340 of 5,911) with videos related to

Pageof 592
Sort By:
The Prostate|November 14, 2024
Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for Progression and Prognostic AssessmentEduardo P Júnior, Egleidson F do Amaral Gomes, Mário F R de Lima, et al.
The Prostate|November 10, 2024
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring SystemToshifumi Takahashi, Masakazu Nakashima, Kouhei Maruno, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
The Prostate|March 13, 2025
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature ReviewMark Willy L Mondia, Prem P Batchala, Robert Dreicer, et al.
The Prostate|October 23, 2024
Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancerIris E Ertl, Ursula Lemberger, Pawel Rajwa, et al.
The Prostate|October 17, 2024
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, et al.
The Prostate|September 2, 2024
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasoundFabian Falkenbach, Fatima Ahmad-Sterkau, Mykyta Kachanov, et al.
The Prostate|August 8, 2024
Expression and immune infiltration studies of IL-33-ST2-NF-κB signaling pathway in prostate cancerHan Wang, Kang He, Yuqi Liu, et al.
The Prostate|July 15, 2024
Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chainTeresa T Liu, Taro Igarashi, Nathalie El-Khoury, et al.
The Prostate|July 11, 2024
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patientsTokiyoshi Tanegashima, Masaki Shiota, Shigehiro Tsukahara, et al.
Pageof 592

Showing results (1331-1340 of 5,911) with videos related to

Sort By:
Pageof 592
The Prostate|November 14, 2024
Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for Progression and Prognostic AssessmentEduardo P Júnior, Egleidson F do Amaral Gomes, Mário F R de Lima, et al.
The Prostate|November 10, 2024
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring SystemToshifumi Takahashi, Masakazu Nakashima, Kouhei Maruno, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
The Prostate|March 13, 2025
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature ReviewMark Willy L Mondia, Prem P Batchala, Robert Dreicer, et al.
The Prostate|October 23, 2024
Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancerIris E Ertl, Ursula Lemberger, Pawel Rajwa, et al.
The Prostate|October 17, 2024
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Wataru Fukuokaya, Shingo Hatakeyama, et al.
The Prostate|September 2, 2024
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasoundFabian Falkenbach, Fatima Ahmad-Sterkau, Mykyta Kachanov, et al.
The Prostate|August 8, 2024
Expression and immune infiltration studies of IL-33-ST2-NF-κB signaling pathway in prostate cancerHan Wang, Kang He, Yuqi Liu, et al.
The Prostate|July 15, 2024
Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chainTeresa T Liu, Taro Igarashi, Nathalie El-Khoury, et al.
The Prostate|July 11, 2024
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patientsTokiyoshi Tanegashima, Masaki Shiota, Shigehiro Tsukahara, et al.
Pageof 592